After vowing to conduct a full audit on the Democratic national political strategy because of the party’s 2024 election losses, Democratic National Committee Chairman Ken Martin says the findings of ...

Like all other BMW models, the 5-Series is being updated as part of the carmaker’s Neue Klasse era, adopting the new styling of recent concepts and the all-electric iX3. However, it appears BMW is ...

Recursion Pharmaceuticals, Inc. (RXRX) recently received a notable upgrade from JP Morgan analyst Eric Joseph, who shifted his rating to “Overweight” on December 17, 2025. This upgrade comes as the ...

Recent victories by Democratic gubernatorial candidates in New Jersey and Virginia and for seats on the Georgia Public Service Commission have led outlets like Politico to brand the outcomes as the ...

Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with content, and download exclusive resources. Vivek Yadav, an engineering manager from ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

Perhaps my worst trait is that I’m a Metroidvania purist. It’s annoying, I know, but I’ve always been fascinated with the awkwardly-named subgenre’s little rules and structures. When I play something ...

After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...

Mayor-elect Zohran Mamdani now says the NYPD should be responsible for responding to domestic violence incidents, backtracking Wednesday on his past controversial comments. The socialist Queens ...

Recursion Pharmaceuticals, Inc. leverages AI to accelerate drug discovery, offering both a licensing platform and an internal drug development pipeline. RXRX faces heavy competition, ongoing operating ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...